OrbiMed

OrbiMed (also known as OrbiMed Advisors) is an American investment firm based in New York City, United States. It is focused on making public and private investments in the Healthcare and Biotechnology industries. OrbiMed is considered to be one of the largest dedicated healthcare investment firms in the world.[3]

OrbiMed Advisors LLC
FormerlyMehta & Isaly
TypePrivate
IndustryFinancial services
Founded1989 (1989)
FounderSamuel Isaly
Michael Sheffery
Arvind Desai
HeadquartersCitigroup Center, New York City, New York, U.S.
ProductsPublic equity
Private equity
Venture capital
Private credit
AUMUS$21 billion (31 March 2021)
Number of employees
100[1]
Websitewww.orbimed.com
Footnotes / references
[2]

History

In 1989, S.G Warburg pharmaceutical analysts, Viren Mehta and Samuel Isaly founded Mehta & Isaly, a money-management and research firm.[4][5] This was the predecessor firm to OrbiMed.

In 1993, the firm made its first private equity investment.[6]

In 1998, Mehta & Isaly split up where Mehta would form Mehta Partners and Isaly would form OrbiMed.[5][7]

In 2007, OrbiMed expanded into Asia opening offices in Shanghai and Mumbai and in 2010, expanded into the Middle East opening a office in Herzliya, Israel.[8]

In 2011, OrbiMed launched its first health care royalties and credit opportunities fund.[8]

In December 2017, Isaly stepped down from his role as managing partner of OrbiMed due to allegations of sexual harassment by former female employees of OrbiMed.[4][9][10]

Business Overview

OrbiMed is headquartered in New York, with additional offices in San Francisco, Mumbai, Shanghai, Hong Kong and Herzliya.[1][3]

The firm has three investment strategies:[8][3]

Public Equity

OrbiMed manages public equity funds that include long/short equity, event-driven investing and closed-end investment trusts. Investments are in publicly traded companies related to Healthcare and Biotechnology.

Private Equity

OrbiMed invests in Startup Companies as well as Mature Companies with a Growth Equity strategy.

Private Credit/Royalty

OrbiMed provides commercial-stage healthcare companies with private debt financing.

Private Equity Funds

North America & Europe
Fund[11] Vintage Year Committed Capital ($m)
OrbiMed Private Investments I 2000 USD 275
OrbiMed Private Investments II 2003 USD 300
OrbiMed Private Investments III 2006 USD 500
OrbiMed Private Investments IV 2010 USD 550
OrbiMed Private Investments V 2013 USD 735
OrbiMed Private Investments VI 2015 USD 950

Asia
Fund[12] Vintage Year Committed Capital ($m)
OrbiMed Asia Partners I 2008 USD 175
OrbiMed Asia Partners II 2014 USD 325
OrbiMed Asia Partners III 2017 USD 551
OrbiMed Asia Partners IV 2020 USD 800

Israel
Fund[13] Vintage Year Committed Capital ($m)
OrbiMed Israel Partners I 2012 USD 222
OrbiMed Israel Partners II 2016 USD 307

Royalty Opportunities
Fund[14] Vintage Year Committed Capital ($m)
OrbiMed Royalty Opportunities Fund I 2011 USD 600
OrbiMed Royalty Opportunities Fund II 2015 USD 924
OrbiMed Royalty and Credit Opportunities III 2019 USD 1,200

Notable investments

References
  1. "Sponsors for the 13th ELSF Forum". SachsForum.
  2. "Form ADV as of 3/30/2021" (PDF). SEC.gov.
  3. "Harbour BioMed Raises $102.8M in Series C Financing to Accelerate Development of Its Innovative Portfolio of Next Generation-hbm holdings". www.harbourbiomed.com.
  4. "ObriMed Advisors founder to step down, be replaced by management committee". Pensions & Investments. 2017-12-08. Retrieved 2021-05-22.
  5. "Mehta & Isaly Investment Firm Splits". The New York Times. 1998-01-06. ISSN 0362-4331. Retrieved 2021-05-22.
  6. Gormley, Brian. "OrbiMed Advisors Offers 'One-Stop Shop' for Health-Care Companies" (PDF). Dow Jones.{{cite web}}: CS1 maint: url-status (link)
  7. "OrbiMed Advisors". FierceBiotech. 8 October 2014. Retrieved 2021-05-22.
  8. "ORBIMED ADVISORS LLC Profile and Investing Strategy - GuruFocus.com". www.gurufocus.com. Retrieved 2021-05-22.
  9. "Isaly steps down from hedge fund giant OrbiMed after harassment claims". STAT. 2017-12-08. Retrieved 2021-05-22.
  10. Norton, Leslie P. "OrbiMed's Sam Isaly Steps Down Amid Accusations of Sexual Misconduct". www.barrons.com. Retrieved 2021-05-22.
  11. "OrbiMed North America & Europe | Palico". www.palico.com. Retrieved 2021-05-22.
  12. "OrbiMed Asia | Palico". www.palico.com. Retrieved 2021-05-22.
  13. "OrbiMed Israel | Palico". www.palico.com. Retrieved 2021-05-22.
  14. "OrbiMed Royalty Opportunities Fund | Palico". www.palico.com. Retrieved 2021-05-22.
  15. "AbCellera Closes $105 Million Series B Financing to Further Advance World-Leading Antibody Drug Discovery Platform". www.abcellera.com. Retrieved 2021-05-22.
  16. Baum, Stephanie (2013-11-01). "OrbiMed closes its largest VC fund, predicts rebound in healthcare investing in 2014". MedCity News. Retrieved 2021-05-22.
  17. "Ambit Biosciences Completes $30 Million Series D-2 Financing". www.businesswire.com. 2011-06-10. Retrieved 2021-05-22.
  18. Reuters Staff (2016-07-07). "BRIEF-Orbimed Advisors acquired 480,000 common shares of Cynapsus Therapeutics". Reuters. Retrieved 2021-05-22. {{cite news}}: |author= has generic name (help)
  19. "DFine raises $36.2M to repair spine fractures". VentureBeat. 2010-07-16. Retrieved 2021-05-22.
  20. Says, Anon (2008-01-03). "Xconomy: Obesity Startup Gelesis Gobbles Up $16M in Financing". Xconomy. Retrieved 2021-05-22.
  21. Inc, Intercept Pharmaceuticals. "Intercept Pharmaceuticals Closes $30 Million Series C Financing". www.prnewswire.com. Retrieved 2021-05-22. {{cite web}}: |last= has generic name (help)
  22. "Natera Completes $54.6 Million Financing to Support Expansion, Continued Global Rollout of Non-Invasive Prenatal Test Panorama™ | Natera, Inc". investor.natera.com. Retrieved 2021-05-22.
  23. Hay, Timothy (2012-08-28). "OmniGuide Raises $35M in Debt From OrbiMed Advisors". Wall Street Journal. ISSN 0099-9660. Retrieved 2021-05-22.
  24. "TigerText Closes on $50 Million in Financing to Accelerate Growth; Launches TigerText Anywhere Initiative". TigerConnect. Retrieved 2021-05-22.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.